Lopez-Cazares Genesis, Eniola-Adefeso Omolola
Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Pharmaceutics. 2022 May 9;14(5):1018. doi: 10.3390/pharmaceutics14051018.
Vascular-targeted carriers (VTCs) have the potential to localize therapeutics and imaging agents to inflamed, diseased sites. Poly (lactic-co-glycolic acid) (PLGA) is a negatively charged copolymer commonly used to construct VTCs due to its biodegradability and FDA approval. Unfortunately, PLGA VTCs experienced reduced adhesion to inflamed endothelium in the presence of human plasma proteins. In this study, PLGA microparticles were coated with chitosan (CS), human serum albumin (HSA), or both (HSA-CS) to improve adhesion. The binding of sialyl Lewis A (a ligand for E-selectin)-targeted PLGA, HSA-PLGA, CSPLGA, and HSA-CSPLGA to activated endothelial cells was evaluated in red blood cells in buffer or plasma flow conditions. PLGA VTCs with HSA-only coating showed improvement and experienced 35-52% adhesion in plasma compared to plasma-free buffer conditions across all shear rates. PLGA VTCs with dual coating-CS and HSA-maintained 80% of their adhesion after exposure to plasma at low and intermediate shears and ≈50% at high shear. Notably, the protein corona characterization showed increases at the 75 and 150 kDa band intensities for HSA-PLGA and HSA-CSPLGA, which could correlate to histidine-rich glycoprotein and immunoglobulin G. The changes in protein corona on HSA-coated particles seem to positively influence particle binding, emphasizing the importance of understanding plasma protein-particle interactions.
血管靶向载体(VTCs)有潜力将治疗剂和成像剂定位到炎症和病变部位。聚乳酸-乙醇酸共聚物(PLGA)是一种带负电荷的共聚物,因其生物可降解性和获得美国食品药品监督管理局(FDA)批准,常用于构建VTCs。不幸的是,在存在人血浆蛋白的情况下,PLGA VTCs对炎症内皮的黏附力降低。在本研究中,用壳聚糖(CS)、人血清白蛋白(HSA)或两者(HSA-CS)包覆PLGA微粒以提高黏附力。在缓冲液或血浆流动条件下,评估了唾液酸化路易斯A(E-选择素的一种配体)靶向的PLGA、HSA-PLGA、CS-PLGA和HSA-CS-PLGA与活化内皮细胞在红细胞中的结合情况。仅用HSA包覆的PLGA VTCs表现出改善,在所有剪切速率下,与无血浆缓冲液条件相比,在血浆中的黏附率为35%-52%。具有CS和HSA双重包覆的PLGA VTCs在低剪切和中剪切下暴露于血浆后保持其80%的黏附力,在高剪切下约为50%。值得注意的是,蛋白质冠层表征显示,HSA-PLGA和HSA-CS-PLGA在75 kDa和150 kDa条带强度增加,这可能与富含组氨酸的糖蛋白和免疫球蛋白G相关。HSA包覆颗粒上蛋白质冠层的变化似乎对颗粒结合有积极影响,强调了理解血浆蛋白-颗粒相互作用的重要性。